高致敏单倍体造血干细胞移植患者采用蛋白 A 免疫吸附联合利妥昔单抗行脱敏治疗的疗效及安全性

Objective To investigate the efficacy and safety of protein A immunoadsorption （PAIA）combined with rituximab（RTX）in highly sensitized patients who underwent haplo-hematopoietic stem cell transplantation（haplo- HSCT）. Methods The clinical data of 56 highly sensitized patients treated with PAIA and RTX before haplo-HSCT at the First Affiliated Hospital of Soochow University and Soochow Hopes Hematonosis Hospital between March 2021 and June 2023 were retrospectively analyzed. The number of human leukocyte antigen（HLA）antibody types and the mean fluorescence intensity （MFI）, humoral immunity, adverse reactions during adsorption, and survival within 100 days before and after adsorption were measured. Results After receiving the PAIA treatment, the median MFI of patients containing only HLA I antibodies decreased from 7 859（3 209 － 12 444） to 3 719（0 － 8 275）（P＜0.001）, and the median MFI of HLA I+Ⅱ antibodies decreased from 5 476（1 977－12 382）to 3 714（0－11 074）（P＝0.035）. The median MFI of patients with positive anti-donor-specific antibodies decreased from 8 779（2 697－18 659）to 4 524（0–15 989）（P＜0.001）. The number of HLA-A, B, C, DR, and DQ antibodies in all patients decreased after the PAIA treatment, and the differences were statistically significant（A, B, C, DR: P＜0.001, DQ: P＜0.01）. The humoral immune monitoring before and after the PAIA treatment showed a significant decrease in the number of IgG and complement C3（P＜0.001 and P＝0.002, respectively）. Forty- four patients underwent HLA antibody monitoring after transplantation, and the overall MFI and number of antibody types decreased. However, five patients developed new antibodies with low MFI, and nine patients continued to have high MFI. The overall survival, disease-free survival, non-recurrent mortality, and cumulative recurrence rates at 100 days post-transplantation were 83.8%, 80.2%, 16.1%, and 4.5%, respectively. Conclusions The combination of PAIA and RTX has a certain therapeutic effect and good safety in the desensitization treatment of highly sensitive patients before haplo-HSCT.